Vaxcyte's new pneumococcal vaccine may only have phase 1/2 results behind it, but analysts are already predicting it could be a major competitor to rival shots from Pfizer and MSD.
Pfizer's longstanding dominance of the pneumococcal vaccines category could be threatened by Merck & Co, which has just reported new data on its V116 shot in older adu
Dominance of the pneumococcal vaccine category is a race between Merck & Co and Pfizer, and while the latter is comfortably in front at the moment with its Prevnar franchise, Merck has
Pfizer's new Prevnar 20 conjugate pneumococcal vaccine can be dosed at the same time as the seasonal flu jab, without any impact on either shot's effectiveness, according to a new study.
Just a month after getting approval for its new pneumococcal vaccine Vaxneuvance in adults, Merck & Co has reported positive trial results in children that will ramp up the pressure on
The FDA has approved a new pneumococcal vaccine from Merck & Co, just over a month after Pfizer got a green light for a new version of its market leading Prevnar shot.